A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Hodgkin Disease
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 72 (final count)
- Started
- Mar 28, 2017
- Main results expected
- May 28, 2024
- Fully finished
- May 28, 2024
- Results posted
- Feb 10, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1
Measured over: From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks).
Event-free Survival (EFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) - Cohort 1
Measured over: At 3 years post first dose of study therapy
Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Blinded Independent Centralized Review (BICR) - Cohort 2
Measured over: From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT02927769 · record last updated 2025-02-10 · checked 2026-11-09 15:47 UTC